Evaluating the Properties of a Dual-Effect Facial Injectable: From Preclinical Data to Real-World Evidence
Patricia Ormiga,Claudia Hernández,Rogério de Lima Romeiro,Aude Bernardin,Fabio Sambatti Crema,Lauren Nakab,Lital Shklanovsky,Graeme Kerson
DOI: https://doi.org/10.2147/ccid.s474587
2024-11-10
Clinical Cosmetic and Investigational Dermatology
Abstract:Patricia Ormiga, 1 Claudia A Hernández, 2 Rogério de Lima Romeiro, 3 Aude Bernardin, 4 Fabio Sambatti Crema, 5 Lauren Nakab, 6 Lital Shklanovsky, 7 Graeme Kerson 8 1 Clínica Patricia Ormiga, Rio de Janeiro, Brazil; 2 CH Dermatologia, Medellin, Antioquia, Colombia; 3 Faculdade São Leopoldo Mandic, Instituto São Leopoldo Mandic, Área de Harmonização Orofacial, São Paulo, Brazil; 4 Allergan Aesthetics, an AbbVie company, Pringy, France; 5 Allergan Aesthetics, an AbbVie company, São Paulo, Brazil; 6 Allergan Aesthetics, an AbbVie company, Irvine, CA, USA; 7 Allergan Aesthetics, an AbbVie company, Lod, Israel; 8 Allergan Aesthetics, an AbbVie company, Marlow, UK Correspondence: Patricia Ormiga, Clínica Patricia Ormiga, Av. Ataulfo de Paiva, 204 – Sala 908, Leblon, Rio de Janeiro, Brazil, Tel +21 98805-1848, Email Facial aging requires a multi-targeted approach for optimal results; however, many combination approaches lack standardization, negatively impacting treatment results. Hyaluronic acid (HA) and calcium hydroxyapatite (CaHA) products are widely used for facial rejuvenation. HA is the gold standard for immediately restoring volume, but it is gradually degraded over time. CaHA acts indirectly by stimulating collagen production and restoring other key extracellular matrix proteins; however, there is a risk of early volume loss due to rapid degradation of the carboxymethylcellulose (CMC) carrier before neocollagenesis occurs. 1 To this end, combining the 2 products can overcome each product's shortcomings and provide immediate and long-term satisfactory outcomes. Such combination treatments have been delivered to patients by manually mixing two separate products into a single syringe. This can change the physicochemical properties of the fillers and can lead to highly variable and inconsistent results due to the lack of validated mixing protocols. HA-CaHA (HArmonyCaTM; Allergan Aesthetics, an AbbVie Company) is a hybrid injectable developed by combining HA with CaHA in a controlled and consistent manner. Importantly, HA-CaHA is a manufactured product supplied as a ready-to-use pre-filled syringe. 2 The key characteristics of HA-CaHA are described here, along with considerations that distinguish this hybrid injectable from a mixture of individual HA and CaHA products. HA-CaHA, developed by an Israel-based company (Panaxia R&D), received regulatory approval in Israel in 2016. The current developers and manufacturers acquired HA-CaHA in 2020 and expanded its approval to over 30 countries. HA-CaHA contains CaHA microspheres (55.7% w/w, approximately 30% by volume) embedded in a crosslinked HA matrix (20 mg/mL) and 0.3% w/v lidocaine. HA-CaHA is created by a stepwise combination of CaHA with HA during crosslinking, resulting in a composite material with dispersed CaHA particles with varying degrees of association with the HA matrix. This combination, manufactured with consistent physiochemical and morphological characteristics, provides a dual mechanism of action. The HA delivers immediate volume and sustained lift, unlike other CaHA products that use CMC carrier, which is degraded faster than HA. 3,4 The CaHA microspheres in HA-CaHA are intended to support fibroblast ingrowth and collagen biostimulation for sustained improvement in skin quality. To confirm that the CaHA in the HA-CaHA combination effectively stimulates neocollagenesis, the study sponsor, Allergan Aesthetics, used a Sprague Dawley rat model to compare the biostimulatory effects of HA-CaHA to the effects of CaHA with CMC carrier, CMC-CaHA (Radiesse ® , Merz Aesthetics), and another biostimulator polycaprolactone with CMC carrier, CMC-PCL (EllanséTM, Sinclair Pharma GmbH). Each product was injected subcutaneously at a volume of 125 μL; tissue was collected at 1- and 8-weeks post injection for chromogenic in situ hybridization (CISH) to measure collagen I gene expression and for immunohistochemistry (IHC) to measure collagen I protein expression. The CISH and IHC signals were quantified and are presented as a total positively stained area per time point. Our results showed that all products stimulated collagen production with no significant difference in the positively stained area at week 1 and 8 time points ( P >.05, Figure 1A and B). These data suggest that the biostimulatory function of CaHA in HA-CaHA is equivalent to that of similar products on the market. Figure 1 Collagen I levels in tissue explants of rats injected with biostimulator products. Quantified tissue staining from ( A ) chromogenic in situ hybridization (CISH) with probes against collagen I mRNA, and ( B ) immunohistochemistry (IHC) with antibodie -Abstract Truncated-
dermatology